115 related articles for article (PubMed ID: 7954349)
1. Tumor localization and therapeutic potential of an antitumor-anti-CD3 heteroconjugate antibody in human renal cell carcinoma xenograft models.
Zhu Z; Ghose T; Lee SH; Fernandez LA; Kerr LA; Donohue JH; McKean DJ
Cancer Lett; 1994 Oct; 86(1):127-34. PubMed ID: 7954349
[TBL] [Abstract][Full Text] [Related]
2. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
[TBL] [Abstract][Full Text] [Related]
3. Tumor localization of monoclonal antibodies against human renal carcinoma in a xenograft model.
Guha AK; Ghose T; Singh M; Aquino J; Blair AH; Luner SJ; Mammen M
Cancer Lett; 1991 Dec; 61(1):35-43. PubMed ID: 1764696
[TBL] [Abstract][Full Text] [Related]
4. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.
van Dijk J; Zegveld ST; Fleuren GJ; Warnaar SO
Int J Cancer; 1991 Jul; 48(5):738-43. PubMed ID: 1830033
[TBL] [Abstract][Full Text] [Related]
5. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT.
Lawrentschuk N; Lee FT; Jones G; Rigopoulos A; Mountain A; O'Keefe G; Papenfuss AT; Bolton DM; Davis ID; Scott AM
Urol Oncol; 2011; 29(4):411-20. PubMed ID: 19523858
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies in human renal cell carcinoma and their use in radioimmune localization and therapy of tumor xenografts.
Lange PH; Vessella RL; Chiou RK; Elson MK; Moon TD; Palme D; Shafer RK
Surgery; 1985 Aug; 98(2):143-50. PubMed ID: 4023915
[TBL] [Abstract][Full Text] [Related]
7. The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts.
Kranenborg MH; Boerman OC; de Weijert MC; Oosterwijk-Wakka JC; Corstens FH; Oosterwijk E
Cancer; 1997 Dec; 80(12 Suppl):2390-7. PubMed ID: 9406688
[TBL] [Abstract][Full Text] [Related]
8. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.
Prewett M; Rothman M; Waksal H; Feldman M; Bander NH; Hicklin DJ
Clin Cancer Res; 1998 Dec; 4(12):2957-66. PubMed ID: 9865906
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.
Bauer S; Oosterwijk-Wakka JC; Adrian N; Oosterwijk E; Fischer E; Wüest T; Stenner F; Perani A; Cohen L; Knuth A; Divgi C; Jäger D; Scott AM; Ritter G; Old LJ; Renner C
Int J Cancer; 2009 Jul; 125(1):115-23. PubMed ID: 19384924
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of allogeneic CD3AK cells on transplanted human renal cell cancer in mice with severe combined immune deficiency.
Ge L; Shan Z; Han Q; Zhang N; Zhao Y
J BUON; 2016; 21(2):399-406. PubMed ID: 27273950
[TBL] [Abstract][Full Text] [Related]
11. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
Luiten RM; Coney LR; Fleuren GJ; Warnaar SO; Litvinov SV
Br J Cancer; 1996 Sep; 74(5):735-44. PubMed ID: 8795576
[TBL] [Abstract][Full Text] [Related]
12. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects.
Kroesen BJ; Janssen RA; Buter J; Nieken J; Sleijfer DT; Mulder NH; De Leij L
J Hematother; 1995 Oct; 4(5):409-14. PubMed ID: 8581377
[TBL] [Abstract][Full Text] [Related]
13. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts.
Sands H; Jones PL; Shah SA; Palme D; Vessella RL; Gallagher BM
Cancer Res; 1988 Jan; 48(1):188-93. PubMed ID: 3334993
[TBL] [Abstract][Full Text] [Related]
14. Application of cytokine drug delivery systems to the immunotherapy of renal cell carcinoma in mice.
Marumo K; Oya M; Murai M; Tazaki H
Int J Urol; 1996 Jan; 3(1 Suppl):S24-7. PubMed ID: 24304015
[TBL] [Abstract][Full Text] [Related]
15. Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen.
van Dijk J; Warnaar SO; van Eendenburg JD; Thienpont M; Braakman E; Boot JH; Fleuren GJ; Bolhuis RL
Int J Cancer; 1989 Feb; 43(2):344-9. PubMed ID: 2521843
[TBL] [Abstract][Full Text] [Related]
16. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: pharmacokinetics and biodistribution of two divalent, ricin-based immunotoxins in xenografted athymic mice.
Faguet GB; Agee JF
Leuk Lymphoma; 1997 May; 25(5-6):509-20. PubMed ID: 9250822
[TBL] [Abstract][Full Text] [Related]
17. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
[TBL] [Abstract][Full Text] [Related]
18. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts.
van Dijk J; Uemura H; Beniers AJ; Peelen WP; Zegveld ST; Fleuren GJ; Warnaar SO; Oosterwijk E
Int J Cancer; 1994 Jan; 56(2):262-8. PubMed ID: 8314310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
